Can unscheduled inpatient length of stay and hospital costs be reduced using 'flash' glucose monitoring?

Interreg diabetes centre for personalised medicine - unscheduled care in diabetes - study 2: inpatient study

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN11565460

Enrollment

Registered

2021-11-10

Start date

2019-10-19

Completion date

Unknown

Last updated

2022-05-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes mellitus Nutritional, Metabolic, Endocrine Diabetes mellitus

Interventions

This is a descriptive developmental mixed-methods study using both qualitative and quantitative approaches with two phases: Phase 2, Part B: pilot study – use of Flash Glucose Monitor

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Phase 2, Part B: pilot study – use of Flash Glucose Monitoring: 1. Adults (aged 18 years and older) 2. Diagnosed with diabetes 3. Admitted to hospital wards defined in phase 1 4. Able to read and understand the participant information sheet (PIS) 5. Able to give written informed consent Phase 2, Part C: pilot study - evaluation interviews: 1. Patients or HCPs that have participated in phase 2, part B 2. Able to read and understand the participant information sheet (PIS) 3. Able to give written informed consent

Exclusion criteria

Exclusion criteria: Phase 2, Part B: pilot study - use of flash glucose monitoring: 1. Children or young people (aged younger than 18 years) 2. Not diagnosed with diabetes 3. Admitted to hospital wards not defined in phase 1 4. Pregnancy or gestational diabetes 5. Significant intercurrent illness and/or terminal diagnosis 6. Have a condition and/or treatment known to affect variability of blood glucose, such as on kidney dialysis 7. Already using a Flash Glucose Monitoring or continuous monitoring device 8. Unable to read and understand the participant information sheet (PIS) 9. Unable to give written informed consent Phase 2, Part C: pilot study - evaluation interviews: 1. Ongoing significant co-morbid illness 2. Unable to read and understand the participant information sheet

Design outcomes

Primary

Measure	Time frame
1. Clinical decision making (changes made to therapy) measured using patient medical records at 4 hourly intervals 2. Patient safety measured using patient medical records at 4 hourly intervals	—

Secondary

Measure	Time frame
Length of stay (LoS) measured using patient medical records at hospital discharge	—

Countries

Ireland, Northern Ireland, Scotland, United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026